18.03.2020 – Medartis Holding AG

Medartis nominates Marco Gadola for election to the Board of Directors

Medartis Holding AG / Key word(s): Personnel
Medartis nominates Marco Gadola for election to the Board of Directors

18-March-2020 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel


Medartis nominates Marco Gadola for election to the Board of Directors

Basel, Switzerland, 18. March 2020 - The Board of Directors of Medartis
Holding AG (SIX: MED), a leading manufacturer and provider of medical
devices for surgical fixation of bone fractures, proposes Marco Gadola for
election as a member of the Board of Directors at the Annual General Meeting
on 17 April 2020. With his proven expertise and leadership experience in the
international medical technology market, Marco Gadola will further
strengthen the Board of Directors and support the company on its growth

The Board of Directors of Medartis Holding AG has decided to propose Marco
Gadola for election as an additional independent member of the Board of
Directors at the Annual General Meeting on 17 April 2020. Following his
election, he is to become a member of the Finance and Audit Committee. All
current members of the Board of Directors and Chairman Dr. h.c. Thomas
Straumann will stand for re-election at the 2020 Annual General Meeting.

From 2013 until the end of 2019, Marco Gadola was Chief Executive Officer of
the Straumann Group, a leading company in the dental market. From 2006 until
2008, he was the Straumann Group's Chief Financial Officer and a member of
its Executive Management Board. In the time between these two positions, he
was Chief Executive Officer Asia Pacific and Chief Financial and Information
Technology Officer at Panalpina Group, where he worked for five years. Prior
to this, he was Chief Financial Officer at Hero and held a number of
leadership positions at Hilti. He began his career at UBS in corporate
finance and at Novartis as a senior auditor. Marco Gadola was born in 1963
and is a Swiss and French citizen. He holds a master's in business
administration and economics from the University of Basel and completed
programs at the London School of Economics and IMD Management School in

Marco Gadola is a member of the Board of Directors of the DKSH Group
(nominated as Chairman), Medacta AG and Calida Group (Chairman). He has also
been put forward for election as Member of the Board of Directors of the
Straumann Group.

Dr. h.c. Thomas Straumann, Chairman of Medartis: "I am very pleased about
the nomination of Marco Gadola as Member of the Board of Directors of
Medartis. I am convinced that with his excellent knowledge of the market,
his extensive international experience and his outstanding track record, he
will make an important contribution to our Board and support the company as
it continues on its growth path."

Coronavirus: information about the Annual General Meeting of Medartis
Holding AG
In order to protect the health of all concerned and in view of the Federal
Council's measures to combat the coronavirus (COVID-19), which were updated
on 16 March 2020, the General Meeting will be held without an audience on 17
April 2020.

In accordance with COVID-19 Regulation 2, Art. 6a para. 1 lit. b, voting
must be exercised via the independent proxy, Neovius AG.

The agenda items for the 2020 Annual General Meeting are scheduled to be
published on the Medartis website on 23 March 2020 at

Patrick Christ
Head Corporate Services
Medartis Holding AG
Phone: +41 61 633 34 70

About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of
the world's leading manufacturers and providers of medical devices for
surgical fixation of bone fractures for upper and lower extremities as well
as for the craniomaxillofacial region. Medartis employs over 600 individuals
across its 13 locations, with products offered in over 50 countries
globally. Medartis is committed to providing surgeons and operating theater
personnel with the most innovative titanium implants and instruments as well
as best in class service. For more information, please visit

This communication does not constitute an offer or invitation to subscribe
for or purchase any securities of Medartis Holding AG. This publication may
contain certain forward-looking statements and assessments or intentions
concerning the company and its business. Such statements involve certain
risks, uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place reliance on these statements,
particularly not in connection with any contract or investment decision. The
company disclaims any obligation to update these forward-looking statements,
assessments or intentions. Further, neither the company nor any of its
directors, officers, employees, agents, counsel or advisers nor any other
person makes any representation or warranty, express or implied, as to, and
accordingly no reliance should be placed on, the accuracy or completeness of
the information contained herein or of the views given or implied.


End of ad hoc announcement